N/A
N=36
The Effect of Salmeterol on Eosinophil (EOS) Function
Allergic Asthma
Bottom Line
View on ClinicalTrials.gov: NCT00214019 ↗Enrolled (actual)
36
Serious AEs
0.0%
Results posted
Aug 2016
Primary outcome: Primary: Sputum Eosinophils (EOS) 24 Hours Post Antigen Challenge — 3.5; 2.4; 0.54; 2.4 Eosinophil percentage
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- salmeterol (Drug); Fluticasone (Drug); Placebo (Drug)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Wisconsin, Madison
- Primary completion
- Jan 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Sputum Eosinophils (EOS) 24 Hours Post Antigen Challenge |
3.5; 2.4; 0.54; 2.4 | — |
Summary
This study is designed to test the hypothesis that salmeterol use, and not fluticasone use or the combination treatment with fluticasone and salmeterol, is associated with a greater number of sputum eosinophils following antigen challenge and, under these circumstances, the migrating peripheral blood eosinophils are less adherent.
Eligibility Criteria
Inclusion Criteria
- 18-55 years of age
- history of asthma symptoms for the previous 6 months
- Forced Expiratory Value (FEV1) >75% of predicted
- positive prick skin test to cat, house dust mite or ragweed
Exclusion Criteria
- history of life threatening asthma or anaphylaxis
- current smoker
- pregnant or breast-feeding
- evidence of an upper respiratory infection within 4 weeks of screening
Data sourced from ClinicalTrials.gov (NCT00214019). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.